General Information of the Protein
Protein ID
PT01273
Protein Name
Ribosomal protein S6 kinase beta-1
Secondarily
Protein Name
70 kDa ribosomal protein S6 kinase 1
Ribosomal protein S6 kinase I
Serine/threonine-protein kinase 14A
p70 ribosomal S6 kinase alpha
Gene Name
RPS6KB1
Secondarily
Gene Name
STK14A
Sequence
MRRRRRRDGFYPAPDFRDREAEDMAGVFDIDLDQPEDAGSEDELEEGGQLNESMDHGGVGPYELGMEHCEKFEISETSVNRGPEKIRPECFELLRVLGKGGYGKVFQVRKVTGANTGKIFAMKVLKKAMIVRNAKDTAHTKAERNILEEVKHPFIVDLIYAFQTGGKLYLILEYLSGGELFMQLEREGIFMEDTACFYLAEISMALGHLHQKGIIYRDLKPENIMLNHQGHVKLTDFGLCKESIHDGTVTHTFCGTIEYMAPEILMRSGHNRAVDWWSLGALMYDMLTGAPPFTGENRKKTIDKILKCKLNLPPYLTQEARDLLKKLLKRNAASRLGAGPGDAGEVQAHPFFRHINWEELLARKVEPPFKPLLQSEEDVSQFDSKFTRQTPVDSPDDSTLSESANQVFLGFTYVAPSVLESVKEKFSFEPKIRSPRRFIGSPRTPVSPVKFSPGDFWGRGASASTANPQTPVEYPMETSGIEQMDVTMSGEASAPLPIRQPNSGPYKKQAFPMISKRPEHLRMNL
    Show/Hide
Organism
Homo sapiens, Human
Protein Classification
Enzyme
>
Kinase
>
Protein Kinase
>
AGC protein kinase group
>
AGC protein kinase RSK family
>
AGC protein kinase p70 subfamily
Function
Serine/threonine-protein kinase that acts downstream of mTOR signaling in response to growth factors and nutrients to promote cell proliferation, cell growth and cell cycle progression (PubMed:11500364, PubMed:12801526, PubMed:14673156, PubMed:15071500, PubMed:15341740, PubMed:16286006, PubMed:17052453, PubMed:17053147, PubMed:17936702, PubMed:18952604, PubMed:19085255, PubMed:19720745, PubMed:19935711, PubMed:19995915, PubMed:23429703, PubMed:28178239, PubMed:22017876). Regulates protein synthesis through phosphorylation of EIF4B, RPS6 and EEF2K, and contributes to cell survival by repressing the pro-apoptotic function of BAD (PubMed:11500364, PubMed:12801526, PubMed:14673156, PubMed:15071500, PubMed:15341740, PubMed:16286006, PubMed:17052453, PubMed:17053147, PubMed:17936702, PubMed:18952604, PubMed:19085255, PubMed:19720745, PubMed:19935711, PubMed:19995915, PubMed:23429703, PubMed:28178239, PubMed:22017876). Under conditions of nutrient depletion, the inactive form associates with the EIF3 translation initiation complex (PubMed:16286006). Upon mitogenic stimulation, phosphorylation by the mechanistic target of rapamycin complex 1 (mTORC1) leads to dissociation from the EIF3 complex and activation (PubMed:16286006). The active form then phosphorylates and activates several substrates in the pre-initiation complex, including the EIF2B complex and the cap-binding complex component EIF4B (PubMed:16286006). Also controls translation initiation by phosphorylating a negative regulator of EIF4A, PDCD4, targeting it for ubiquitination and subsequent proteolysis (PubMed:17053147). Promotes initiation of the pioneer round of protein synthesis by phosphorylating POLDIP3/SKAR (PubMed:15341740). In response to IGF1, activates translation elongation by phosphorylating EEF2 kinase (EEF2K), which leads to its inhibition and thus activation of EEF2 (PubMed:11500364). Also plays a role in feedback regulation of mTORC2 by mTORC1 by phosphorylating RICTOR, resulting in the inhibition of mTORC2 and AKT1 signaling (PubMed:19720745, PubMed:19935711, PubMed:19995915). Also involved in feedback regulation of mTORC1 and mTORC2 by phosphorylating DEPTOR (PubMed:22017876). Mediates cell survival by phosphorylating the pro-apoptotic protein BAD and suppressing its pro-apoptotic function (By similarity). Phosphorylates mitochondrial URI1 leading to dissociation of a URI1-PPP1CC complex (PubMed:17936702). The free mitochondrial PPP1CC can then dephosphorylate RPS6KB1 at Thr-412, which is proposed to be a negative feedback mechanism for the RPS6KB1 anti-apoptotic function (PubMed:17936702). Mediates TNF-alpha-induced insulin resistance by phosphorylating IRS1 at multiple serine residues, resulting in accelerated degradation of IRS1 (PubMed:18952604). In cells lacking functional TSC1-2 complex, constitutively phosphorylates and inhibits GSK3B (PubMed:17052453). May be involved in cytoskeletal rearrangement through binding to neurabin (By similarity). Phosphorylates and activates the pyrimidine biosynthesis enzyme CAD, downstream of MTOR (PubMed:23429703). Following activation by mTORC1, phosphorylates EPRS and thereby plays a key role in fatty acid uptake by adipocytes and also most probably in interferon-gamma-induced translation inhibition (PubMed:28178239).
    Show/Hide
Uniprot ID
Primary ID:
P23443

Secondarily ID:
B2R779
B4DLT4
B4DTG1
E7ESB8
F6UYM1
Q7Z721
    Show/Hide
Ensembl ID
ENSG00000108443
HGNC ID
HGNC:10436
Subcellular Location
Synapse
Synaptosome
Mitochondrion outer membrane
Mitochondrion
Map of Molecular Bioactivity Related to the Protein
Map of Molecular Bioactivity Related to the Protein

Protein
Cell Line
Compound

Bioactivity Value:

<= 0.1 μM
> 0.1 μM and <= 10 μM
> 10 μM
Imprecise Activity
Table of Molecular Bioactivities Related to the Protein
Cell Line ID: CL000068 , A-549
Compound ID Compound Name Compound Formula
CP0322941
3-[4-(3-bromo-2H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-methyl-5-(3-methyl-1,2,4-oxadiazol-5-yl)-N-(2-pyrrolidin-1-ylethyl)aniline
   Show/Hide
C25H31BrN10O
 1
1
IC50 = 13 nM
   TI
   LI
   LO
   TS
CP0146238
3-[4-(3-bromo-2H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-4-methyl-N-phenyl-5-(2-pyrrolidin-1-ylethylamino)benzamide
   Show/Hide
C29H34BrN9O
 1
1
IC50 = 14 nM
   TI
   LI
   LO
   TS
CP0146240
3-[4-(3-bromo-2H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-methyl-N-(2-pyrrolidin-1-ylethyl)-5-(2,2,2-trifluoroethoxymethyl)aniline
   Show/Hide
C25H32BrF3N8O
 1
1
IC50 = 17 nM
   TI
   LI
   LO
   TS
CP0073616
1-[3-[4-(3-bromo-2H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-4-methyl-5-(2-pyrrolidin-1-ylethylamino)phenyl]propan-1-one
   Show/Hide
C25H33BrN8O
 1
1
IC50 = 18 nM
   TI
   LI
   LO
   TS
CP0315540
1-[3-[4-(3-bromo-2H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-4-methyl-5-(2-pyrrolidin-1-ylethylamino)phenyl]-4,4,4-trifluorobutan-1-one
   Show/Hide
C26H32BrF3N8O
 1
1
IC50 = 30 nM
   TI
   LI
   LO
   TS
CP0192555
3-[4-(3-bromo-2H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-methyl-5-(2-methylpropoxy)-N-(2-pyrrolidin-1-ylethyl)aniline
   Show/Hide
C26H37BrN8O
 1
1
IC50 = 37 nM
   TI
   LI
   LO
   TS
CP0248530
N-[3-[4-(3-bromo-2H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-5-chloro-2-methylphenyl]-N',N'-dimethylethane-1,2-diamine
   Show/Hide
C20H26BrClN8
 1
1
IC50 = 43 nM
   TI
   LI
   LO
   TS
CP0247186
methyl 3-[4-(3-bromo-2H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-4-methyl-5-(2-pyrrolidin-1-ylethylamino)benzoate
   Show/Hide
C24H31BrN8O2
 1
1
IC50 = 44 nM
   TI
   LI
   LO
   TS
CP0125121
N-[5-chloro-3-[4-(3-ethyl-2H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-methylphenyl]-N',N'-dimethylethane-1,2-diamine
   Show/Hide
C22H31ClN8
 1
1
IC50 = 45 nM
   TI
   LI
   LO
   TS
CP0272288
5-chloro-3-[4-(3-ethyl-2H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-methyl-N-(2-pyrrolidin-1-ylethyl)aniline
   Show/Hide
C24H33ClN8
 1
1
IC50 = 80 nM
   TI
   LI
   LO
   TS
CP0151040
3-[4-(3-bromo-2H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-5-chloro-2-methyl-N-(2-pyrrolidin-1-ylethyl)aniline
   Show/Hide
C22H28BrClN8
 1
1
IC50 = 94 nM
   TI
   LI
   LO
   TS
CP0237101
3-[4-(3-bromo-2H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-5-(3,3-dimethylbutyl)-2-methyl-N-(2-pyrrolidin-1-ylethyl)aniline
   Show/Hide
C28H41BrN8
 1
1
IC50 = 116 nM
   TI
   LI
   LO
   TS
CP0073613
3-[4-(3-bromo-2H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-5-ethoxy-2-methyl-N-(2-pyrrolidin-1-ylethyl)aniline
   Show/Hide
C24H33BrN8O
 1
1
IC50 = 197 nM
   TI
   LI
   LO
   TS
Biochemical Assays
Compound ID Compound Name Compound Formula
CP0073616
1-[3-[4-(3-bromo-2H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-4-methyl-5-(2-pyrrolidin-1-ylethylamino)phenyl]propan-1-one
   Show/Hide
C25H33BrN8O
 1
1 IC50 = 1 nM
CP0146238
3-[4-(3-bromo-2H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-4-methyl-N-phenyl-5-(2-pyrrolidin-1-ylethylamino)benzamide
   Show/Hide
C29H34BrN9O
 1
1 IC50 = 1 nM
CP0192555
3-[4-(3-bromo-2H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-methyl-5-(2-methylpropoxy)-N-(2-pyrrolidin-1-ylethyl)aniline
   Show/Hide
C26H37BrN8O
 1
1 IC50 = 1 nM
CP0322941
3-[4-(3-bromo-2H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-methyl-5-(3-methyl-1,2,4-oxadiazol-5-yl)-N-(2-pyrrolidin-1-ylethyl)aniline
   Show/Hide
C25H31BrN10O
 1
1 IC50 = 1 nM
CP0073613
3-[4-(3-bromo-2H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-5-ethoxy-2-methyl-N-(2-pyrrolidin-1-ylethyl)aniline
   Show/Hide
C24H33BrN8O
 1
1 IC50 = 2 nM
CP0125121
N-[5-chloro-3-[4-(3-ethyl-2H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-methylphenyl]-N',N'-dimethylethane-1,2-diamine
   Show/Hide
C22H31ClN8
 1
1 IC50 = 2 nM
CP0146240
3-[4-(3-bromo-2H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-methyl-N-(2-pyrrolidin-1-ylethyl)-5-(2,2,2-trifluoroethoxymethyl)aniline
   Show/Hide
C25H32BrF3N8O
 1
1 IC50 = 2 nM
CP0151040
3-[4-(3-bromo-2H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-5-chloro-2-methyl-N-(2-pyrrolidin-1-ylethyl)aniline
   Show/Hide
C22H28BrClN8
 1
1 IC50 = 2 nM
CP0237101
3-[4-(3-bromo-2H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-5-(3,3-dimethylbutyl)-2-methyl-N-(2-pyrrolidin-1-ylethyl)aniline
   Show/Hide
C28H41BrN8
 1
1 IC50 = 2 nM
CP0247186
methyl 3-[4-(3-bromo-2H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-4-methyl-5-(2-pyrrolidin-1-ylethylamino)benzoate
   Show/Hide
C24H31BrN8O2
 1
1 IC50 = 2 nM
CP0248530
N-[3-[4-(3-bromo-2H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-5-chloro-2-methylphenyl]-N',N'-dimethylethane-1,2-diamine
   Show/Hide
C20H26BrClN8
 1
1 IC50 = 2 nM
CP0315540
1-[3-[4-(3-bromo-2H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-4-methyl-5-(2-pyrrolidin-1-ylethylamino)phenyl]-4,4,4-trifluorobutan-1-one
   Show/Hide
C26H32BrF3N8O
 1
1 IC50 = 2 nM
CP0272288
5-chloro-3-[4-(3-ethyl-2H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-methyl-N-(2-pyrrolidin-1-ylethyl)aniline
   Show/Hide
C24H33ClN8
 1
1 IC50 = 3 nM
Clinical Information about the Protein
Target 1 ( Ribosomal protein S6 kinase beta-1 (S6K1) )
Target Type Clinical trial Target
Disease 2 Target-related Diseases  2
1 Solid tumour/cancer [ICD-11: 2A00-2F9Z]
2 Ulcerative colitis [ICD-11: DD71]
Clinical Trial Drug(s) 2 Clinical Trial Drugs  2
1 M2698 Phase 1
Solid tumour/cancer
2 PF-4708671 Clinical trial
Ulcerative colitis
Investigative Drug(s) 1 Investigative Drug  1
1 ACTB-1003 Investigative
Solid tumour/cancer